Lobbying Update: $50,000 of NEUROCRINE BIOSCIENCES INC. lobbying was just disclosed

$50,000 of NEUROCRINE BIOSCIENCES INC. lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing.

This included lobbying on issues like:

"Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients."

You can find more data on corporate lobbying on Quiver Quantitative.

NBIX Insider Trading Activity

NBIX insiders have traded $NBIX stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.

Here’s a breakdown of recent trading of $NBIX stock by insiders over the last 6 months:

• INGRID DELAET (Chief Regulatory Officer) has traded it 5 times. They made 0 purchases and 5 sales, selling 8,779 shares.
• JUDE ONYIA (Chief Scientific Officer) sold 2,331 shares.
• DAVID W. BOYER (Chief Corp. Affairs Officer) has traded it 2 times. They made 0 purchases and 2 sales, selling 4,756 shares.
• WILLIAM H RASTETTER sold 14,250 shares.
• MATT ABERNETHY (Chief Financial Officer) sold 14,100 shares.
• GARY A LYONS sold 11,570 shares.
• DARIN LIPPOLDT (Chief Legal Officer) sold 2,996 shares.
• JULIE COOKE (Chief Human Resources Officer) sold 12,632 shares.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

NBIX Hedge Fund Activity

We have seen 290 institutional investors add shares of NBIX stock to their portfolio, and 279 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• CITADEL ADVISORS LLC added 1,023,651 shares (+138.2%) to their portfolio in Q3 2024
• JPMORGAN CHASE & CO removed 864,804 shares (-36.6%) from their portfolio in Q3 2024
• ARMISTICE CAPITAL, LLC removed 797,107 shares (-81.5%) from their portfolio in Q3 2024
• DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) added 625,586 shares (+90.5%) to their portfolio in Q3 2024
• AQR CAPITAL MANAGEMENT LLC added 620,226 shares (+50.7%) to their portfolio in Q3 2024
• POLAR CAPITAL HOLDINGS PLC removed 590,552 shares (-96.7%) from their portfolio in Q3 2024
• 1832 ASSET MANAGEMENT L.P. removed 541,200 shares (-100.0%) from their portfolio in Q3 2024

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.